NCT03523585 2026-02-27
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Phase 3 Completed
Daiichi Sankyo
National Cancer Institute (NCI)
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Puma Biotechnology, Inc.
Novartis
National Cancer Institute (NCI)
Novartis
Novartis
Hoffmann-La Roche
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline